The effect of PARP inhibitors on PD-L1 expression highlights the need to combine these compounds with anti-PD-L1 treatment or PD-1 blockade to maximize the anticancer feedback from immune cells and improve the therapeutic outcome for cancer patients. The gene discussed is PARP1; the disease is cancer.